Adicet Bio (ACET) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
RenovoRx (RNXT) has outperformed Adicet Bio (ACET) over the past year, gaining 9.9% versus a loss of 61.4%. Over five years, RNXT leads with a -77.8% price change compared with -95.5% for ACET. RenovoRx is the larger company by market cap ($60.0 million vs $53.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | RNXT |
|---|---|---|
| Share price | $5.74 | $1.33 |
| Market cap | $53.73M | $60.02M |
| 1-day change | -7.12% | -2.92% |
| YTD return | -31.83% | +58.33% |
| 1-year return | -61.38% | +9.92% |
| 5-year return | -95.54% | -77.76% |
| EPS (TTM) | $-10.42 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $2.59 |
| 52-week low | $5.55 | $0.701 |
| Distance from 52-week high | -67.09% | -48.65% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +506.79% | +436.09% |
| Average volume | 172.38K | 761.09K |
| Shares outstanding | 9.36M | 45.13M |
| Employees | 102 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed ACET by 71.3 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Healthcare · Biotechnology · 102 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Healthcare · Biotechnology · 17 employees
ACET vs RNXT FAQ
Which is bigger, Adicet Bio or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $60.02M compared with $53.73M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or RNXT?
RNXT returned +9.92% over the past 12 months, compared with -61.38% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.